Increased intensity of acute graft-versus-host disease after reduced-intensity bone marrow transplantation compared to conventional transplantation from an HLA-matched sibling in children

Bone Marrow Transplantation

Volumn 37, Issue 6, 2006, Pages 601-605

  Inoue, M ^a   Okamura, T ^a   Yasui, M ^a   Sawada, A ^a   Sakata, N ^a   Koyama, M ^a   Sakata, A ^a   Takeshita, Y ^a   Kouroki, M ^a   Yagi, K ^a   Kawa, K ^a  

^a RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

Author keywords

Acute GVHD; Children; CST; RIST

Indexed keywords

CYCLOSPORIN A; FLUDARABINE; MELPHALAN; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW DEPRESSION; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC GRANULOMATOUS DISEASE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HLA MATCHING; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; INFANT; JUVENILE MYELOMONOCYTIC LEUKEMIA; NEUROBLASTOMA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SIBLING; VIRUS INFECTION;

ADOLESCENT; BONE MARROW TRANSPLANTATION; CELL COUNT; CHILD; CHILD, PRESCHOOL; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; INCIDENCE; INFANT; JAPAN; LEUKEMIA; LYMPHOMA; MALE; NEOPLASMS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION;

EID: 33644930579     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705285     Document Type: Article

References (25)

1. Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
2. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
3. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
4. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
5. Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003; 102: 2021-2030.
6. Hamaki T, Kami M, Kanda Y, Yuji K, Inamoto Y, Kishi Y et al. Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: A retrospective study of 33 patients. Bone Marrow Transplant 2005; 35: 549-556.
7. Kusumi E, Kami M, Kanda Y, Murashige N, Kishi Y, Suzuki R et al. Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: A retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant 2005; 36: 205-213.
8. Amrolia P, Gaspar HB, Hassan A, Webb D, Jones A, Sturt N et al. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 2000; 96: 1239-1246.
9. Del Toro G, Satwani P, Harrison L, Cheung Y-K, Brigid Bradley M, George D et al. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 2004; 33: 613-622.
10. Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004; 364: 156-162.
11. ll Koyama M, Nakano T, Takeshita Y, Sakata A, Sawada A, Yasui M et al. Successful treatment of JMML with related bone marrow transplantation after reduced-intensity conditioning. Bone Marrow Transplant 2005; 36: 453-454.
12. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
13. Martino R, Caballero MD, Pérez Simón JA, Canals C, Solano C, Urbano-Ispízua A et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100: 2243-2245.
14. Schetelig J, Thiede C, Bornhäuser M, Schwerdtfeger R, Kiehl M, Beyer J et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: The cooperative german transplant study group. J Clin Oncol 2003; 21: 2747-2753.
15. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 441-1145.
16. Mineishi S, Kanda Y, Saito T, Nakai K, Makimoto A, Kami M et al. Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies. Br J Haematol 2003; 121: 296-303.
17. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993-2003.
18. Okamura J, Utsunomiya A, Tanosaki R, Uike N, Sonoda S, Kannagi M et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/ lymphoma. Blood 2005; 105: 4143-4145.
19. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
20. Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8: 575-581.
21. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021-1028.
22. Mattsson J, Uzunel M, Remberger M, Ringden O. T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2001; 71: 433-139.
23. Mielcarek M, Martin PJ, Leisenring W, Flowers M-ED, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-762.
24. Perez-Simon JA, Diez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. Br J Haematol 2005 130: 394-403.
25. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.